Oxinas Partners Wealth Management LLC Increases Stock Holdings in Global X Genomics & Biotechnology ETF $GNOM

Oxinas Partners Wealth Management LLC increased its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 12.1% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 16,212 shares of the company’s stock after acquiring an additional 1,751 shares during the period. Oxinas Partners Wealth Management LLC owned approximately 0.32% of Global X Genomics & Biotechnology ETF worth $137,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GNOM. Creative Financial Designs Inc. ADV purchased a new stake in shares of Global X Genomics & Biotechnology ETF during the first quarter valued at approximately $95,000. HighTower Advisors LLC boosted its stake in shares of Global X Genomics & Biotechnology ETF by 16.7% in the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock valued at $121,000 after purchasing an additional 2,184 shares during the period. Smartleaf Asset Management LLC grew its holdings in Global X Genomics & Biotechnology ETF by 18.5% during the 1st quarter. Smartleaf Asset Management LLC now owns 14,933 shares of the company’s stock valued at $125,000 after purchasing an additional 2,329 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Global X Genomics & Biotechnology ETF during the 4th quarter worth $148,000. Finally, Comprehensive Money Management Services LLC increased its stake in Global X Genomics & Biotechnology ETF by 10.9% during the 1st quarter. Comprehensive Money Management Services LLC now owns 20,355 shares of the company’s stock worth $162,000 after buying an additional 2,000 shares during the period. Institutional investors and hedge funds own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM stock opened at $37.89 on Thursday. The company’s fifty day moving average price is $36.34 and its two-hundred day moving average price is $33.85. The firm has a market capitalization of $47.36 million, a P/E ratio of -16.19 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a 12 month low of $27.20 and a 12 month high of $45.16.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.